Cytek Biosciences, Inc. — 2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023. This is an annual filing, not a standalone fourth-quarter report; the provided filing text does not give a complete set of Q4-only financial results.
Business context and results
Cytek develops and sells cell-analysis instruments, reagents, software and services, including its Full Spectrum Profiling platform. The February 2023 acquisition of Luminex’s flow cytometry and imaging business added Amnis and Guava products. Acquired-business revenue was $28.7 million for the year.
- Revenue: $193.0 million, up 18% from $164.0 million. Excluding the acquired business, organic revenue increased 0.2%.
- Revenue mix: Product revenue was $156.7 million, up 5%; service revenue was $36.3 million, up 135%. Direct sales generated 76% of revenue, versus 79% in 2022.
- Profitability: Gross profit was $109.4 million, up 8%; gross margin declined to 57% from 62%. Product gross margin fell to 58% from 66%, while service gross margin rose to 50% from 15%.
- Operating results: Operating loss was $27.8 million, compared with a $1.8 million loss in 2022. Net loss was $12.1 million, versus net income of $2.5 million; loss per share was $0.09.
- Cash flow: Operating cash flow was positive $5.3 million, compared with negative $12.2 million in 2022. Investing activities used $93.9 million and financing activities used $41.8 million. Cash, cash equivalents and restricted cash decreased by $131.9 million.
- Liquidity and debt: Cash and cash equivalents were $167.3 million, short-term marketable securities $95.1 million, and restricted cash $0.3 million at year-end. Total cash, cash equivalents and restricted cash was $167.6 million. Debt was approximately $2.2 million, including current and noncurrent portions.
- Other metrics: R&D expense rose 27% to $44.2 million; sales and marketing expense rose 48% to $49.1 million; G&A expense rose 27% to $44.0 million. Share repurchases totaled $44.0 million for the year.
Material changes versus 2022
- Reported revenue growth included the acquired FCI business; management reported only 0.2% organic growth.
- Operating expenses increased to $137.3 million from $102.8 million, reflecting investment in personnel, R&D, sales and marketing, and acquisition-related operations.
- Gross margin decreased, with management citing higher material costs and a less favorable instrument mix after the acquisition. The larger service business and more instruments coming off warranty supported improved service margins.
- Cash and cash equivalents fell from $296.6 million to $167.3 million. The decline included acquisition spending, marketable-security purchases and share repurchases.
Outlook, risks and unusual items
- Outlook: No numerical revenue or earnings guidance is provided in the filing text. Management expects continued investment and increases in R&D, sales and marketing, and G&A expenses. It says existing cash and anticipated operating cash flows are expected to cover working capital and capital expenditure needs for at least 12 months from the filing date.
- Demand and execution: Management cited macroeconomic uncertainty and longer sales cycles among U.S. biotech and pharmaceutical customers as factors that adversely affected 2023 results. Instrument sales cycles can be six months or longer, and revenue may fluctuate seasonally and by quarter.
- Key risks: Revenue remains substantially dependent on core instruments; the company relies on limited or sole-source suppliers for certain components; academic and government research budgets influence demand; and U.S. clinical-market expansion depends partly on regulatory clearances or approvals. Competition, international operations, and currency movements also pose risks.
- Controls and filing: Management concluded disclosure controls and internal control over financial reporting were ineffective at year-end because of material weaknesses involving accounting and IT staffing, IT access controls, journal-entry controls and account reconciliations. Deloitte issued an adverse opinion on internal control, while giving an unqualified opinion on the financial statements. The company disclosed that it used Form 12b-25 and made adjustments to certain 2023 financial-statement line items during the year-end close.
- Other items: The company paid $44.0 million to repurchase shares and accrued $0.3 million of related excise tax. A $19.0 million liability remains under the BD settlement and license agreement. The filing reports $14.9 million of 2023 revenue from bill-and-hold arrangements, including $5.4 million for products not yet shipped at year-end. No material pending legal proceedings were reported.
Important facts for investors to verify
- How much of future growth comes from the acquired FCI business versus organic demand, particularly for core instruments.
- Whether management remediates the disclosed material weaknesses and whether controls operate effectively in subsequent filings.
- Whether gross margins recover as manufacturing efficiency improves and product, service and distributor revenue mix changes.
- Whether customer sales cycles, research funding and demand support the company’s spending plans and stated liquidity runway.
- The terms, timing and cash impact of the remaining BD settlement liability, debt and any subsequent borrowing against the Wuxi property.
- The revenue-recognition judgments and collection or delivery status associated with bill-and-hold sales.